Kathleen E Walsh1, Sarah L Cutrona2, Patricia L Kavanagh3, Lori E Crosby4, Chris Malone5, Katie Lobner6, David G Bundy7. 1. Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati School of Medicine, Cincinnati, Ohio; Departments of Pediatrics, and Meyers Primary Care Institute, Worcester, Massachusetts; Kathleen.walsh@cchmc.org. 2. Meyers Primary Care Institute, Worcester, Massachusetts; Medicine, University of Massachusetts, Worcester, Massachusetts; 3. Department of Pediatrics, Boston University, Boston, Massachusetts; 4. Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati School of Medicine, Cincinnati, Ohio; 5. Meyers Primary Care Institute, Worcester, Massachusetts; 6. Welch Medical Library, Johns Hopkins Medical Center, Baltimore, Maryland; and. 7. Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina.
Abstract
OBJECTIVES: Describe rates of adherence for sickle cell disease (SCD) medications, identify patient and medication characteristics associated with nonadherence, and determine the effect of nonadherence and moderate adherence (defined as taking 60%-80% of doses) on clinical outcomes. METHODS: In February 2012 we systematically searched 6 databases for peer-reviewed articles published after 1940. We identified articles evaluating medication adherence among patients <25 years old with SCD. Two authors reviewed each article to determine whether it should be included. Two authors extracted data, including medication studied, adherence measures used, rates of adherence, and barriers to adherence. RESULTS: Of 24 articles in the final review, 23 focused on 1 medication type: antibiotic prophylaxis (13 articles), iron chelation (5 articles), or hydroxyurea (5 articles). Adherence rates ranged from 16% to 89%; most reported moderate adherence. Medication factors contributed to adherence. For example, prophylactic antibiotic adherence was better with intramuscular than oral administration. Barriers included fear of side effects, incorrect dosing, and forgetting. Nonadherence was associated with more vaso-occlusive crises and hospitalizations. The limited data available on moderate adherence to iron chelation and hydroxyurea indicates some clinical benefit. CONCLUSIONS: Moderate adherence is typical among pediatric patients with SCD. Multicomponent interventions are needed to optimally deliver life-changing medications to these children and should include routine monitoring of adherence, support to prevent mistakes, and education to improve understanding of medication risks and benefits.
OBJECTIVES: Describe rates of adherence for sickle cell disease (SCD) medications, identify patient and medication characteristics associated with nonadherence, and determine the effect of nonadherence and moderate adherence (defined as taking 60%-80% of doses) on clinical outcomes. METHODS: In February 2012 we systematically searched 6 databases for peer-reviewed articles published after 1940. We identified articles evaluating medication adherence among patients <25 years old with SCD. Two authors reviewed each article to determine whether it should be included. Two authors extracted data, including medication studied, adherence measures used, rates of adherence, and barriers to adherence. RESULTS: Of 24 articles in the final review, 23 focused on 1 medication type: antibiotic prophylaxis (13 articles), iron chelation (5 articles), or hydroxyurea (5 articles). Adherence rates ranged from 16% to 89%; most reported moderate adherence. Medication factors contributed to adherence. For example, prophylactic antibiotic adherence was better with intramuscular than oral administration. Barriers included fear of side effects, incorrect dosing, and forgetting. Nonadherence was associated with more vaso-occlusive crises and hospitalizations. The limited data available on moderate adherence to iron chelation and hydroxyurea indicates some clinical benefit. CONCLUSIONS: Moderate adherence is typical among pediatric patients with SCD. Multicomponent interventions are needed to optimally deliver life-changing medications to these children and should include routine monitoring of adherence, support to prevent mistakes, and education to improve understanding of medication risks and benefits.
Authors: Kathleen E Walsh; Kathleen M Mazor; Christopher J Stille; Irma Torres; Joann L Wagner; Juliet Moretti; Kevin Chysna; Christy D Stine; G Naheed Usmani; Jerry H Gurwitz Journal: Arch Dis Child Date: 2011-03-27 Impact factor: 3.791
Authors: Kathleen E Walsh; Kathleen M Mazor; Douglas Roblin; Colleen Biggins; Joann L Wagner; Kathleen Houlahan; Justin W Li; Christopher Keuker; Karen Wasilewski-Masker; Jennifer Donovan; Abir Kanaan; Saul N Weingart Journal: J Oncol Pract Date: 2013-01 Impact factor: 3.840
Authors: Sarah L Reeves; Hannah K Jary; Jennifer P Gondhi; Jean L Raphael; Lynda D Lisabeth; Kevin J Dombkowski Journal: Clin Pediatr (Phila) Date: 2019-05-21 Impact factor: 1.168
Authors: Najibah A Galadanci; Shehu Umar Abdullahi; Leah D Vance; Abdulkadir Musa Tabari; Shehi Ali; Raymond Belonwu; Auwal Salihu; Aisha Amal Galadanci; Binta Wudil Jibir; Halima Bello-Manga; Kathleen Neville; Fenella J Kirkham; Yu Shyr; Sharon Phillips; Brittany V Covert; Adetola A Kassim; Lori C Jordan; Muktar H Aliyu; Michael R DeBaun Journal: Am J Hematol Date: 2017-06-15 Impact factor: 10.047